argenx SE — AGM Information 2018

Mar 26, 2018

6-K 1 a18-8986_16k.htm 6-K

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*WASHINGTON, D.C. 20549*

*FORM 6-K*

*REPORT OF FOREIGN PRIVATE ISSUER*

*PURSUANT TO RULE 13a-16 OR 15d-16*

*UNDER THE SECURITIES EXCHANGE ACT OF 1934*

*For the Month of March 2018*

*Commission File Number: 001-38097*

*ARGENX SE*

(Translation of registrant’s name into English)

*Willemstraat 5 4811 AH, Breda, the Netherlands*

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

SEQ.=1,FOLIO='',FILE='C:\JMS\C902501\18-8986-1\task8804932\8986-1-ba.htm',USER='C902501',CD='Mar 26 21:42 2018'

*EXPLANATORY NOTE*

On March 26, 2018, argenx SE issued a press release announcing that the European Commission has granted orphan status for the use of ARGX-113 for the treatment of myasthenia gravis in Europe. This press release is enclosed hereto as Exhibit 99.1 and is incorporated herein by reference.

Enclosed hereto as Exhibits 99.2, 99.3, 99.4, 99.5, and 99.6 and incorporated herein by reference are copies of the formal notice of convocation, agenda, and other ancillary documents relevant for argenx SE’s Annual General Meeting of Shareholders that will be held on Tuesday, May 8, 2018 at 10:00 a.m. (CET), at Hilton Amsterdam Airport Schiphol, Schiphol Boulevard 701, 1118 BG Schiphol, the Netherlands.

*EXHIBITS*

Exhibit	Description
99.1	Press Release titled “argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe” dated March 26, 2018
99.2	Press Release titled “argenx announces Annual General Meeting of Shareholders on May 8, 2018” dated March 26, 2018
99.3	Notice of Convocation for the Annual General Meeting of Shareholders of argenx SE to be held on May 8, 2018
99.4	Proxy Form for the Annual General Meeting of Shareholders to be held on May 8, 2018
99.5	Agenda for the Annual General Meeting of Shareholders to be held on May 8, 2018
99.6	Explanatory Notes for the Annual General Meeting of Shareholders to be held on May 8, 2018
99.7	Voting Instruction Form for holders of American Depositary Shares for the Annual General Meeting of Shareholders to be held on May 8, 2018

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\C902501\18-8986-1\task8804932\8986-1-ba.htm',USER='C902501',CD='Mar 26 21:42 2018'

*SIGNATURES*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

/s/ Dirk Beeusaert
Dirk Beeusaert
General Counsel

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\C902501\18-8986-1\task8804932\8986-1-ba.htm',USER='C902501',CD='Mar 26 21:42 2018'